Evidence map›Paper›PMID 38140560›Full record

ArticleViruses2023

Development of an Oral IgA Response against SARS-CoV-2 Following Immunization with Different COVID-19 Vaccines.

Irene Soffritti, Maria D'Accolti, Francesca Bini, Eleonora Mazziga, Davide Proietto, Beatrice Dallan, Martina De Laurentis, Sara Ghisellini, Francesco Nicoli, Elisabetta Caselli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Irene SoffrittiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), Section of Microbiology, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-5274-295X
Maria D'AccoltiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), Section of Microbiology, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0003-1937-5534
Francesca BiniDepartment of Chemical, Pharmaceutical and Agricultural Sciences, and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), Section of Microbiology, University of Ferrara, 44121 Ferrara, Italy.
Eleonora MazzigaDepartment of Chemical, Pharmaceutical and Agricultural Sciences, and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), Section of Microbiology, University of Ferrara, 44121 Ferrara, Italy.
Davide ProiettoDepartment of Chemical, Pharmaceutical and Agricultural Sciences, Laboratory of Biochemistry, Immunology and Microbiology (BIM), University of Ferrara, 44123 Ferrara, Italy.ORCID 0000-0002-3507-833X
Beatrice DallanDepartment of Chemical, Pharmaceutical and Agricultural Sciences, Laboratory of Biochemistry, Immunology and Microbiology (BIM), University of Ferrara, 44123 Ferrara, Italy.
Martina De LaurentisDepartment of Chemical, Pharmaceutical and Agricultural Sciences, Laboratory of Biochemistry, Immunology and Microbiology (BIM), University of Ferrara, 44123 Ferrara, Italy.
Sara GhiselliniLaboratory of Clinical Pathology, University Hospital St. Anna, 44121 Ferrara, Italy.
Francesco NicoliDepartment of Chemical, Pharmaceutical and Agricultural Sciences, Laboratory of Biochemistry, Immunology and Microbiology (BIM), University of Ferrara, 44123 Ferrara, Italy.ORCID 0000-0001-6327-5958
Elisabetta CaselliDepartment of Chemical, Pharmaceutical and Agricultural Sciences, and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), Section of Microbiology, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-6048-9141
University of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mucosal immune response is recognized to be important in the early control of infection sustained by viruses with mucosal tissues as the primary site of entry and replication, such as SARS-CoV-2. Mucosal IgA has been consistently reported in the mouth and eye of SARS-CoV-2 infected subjects, where it correlated inversely with COVID-19 symptom severity. Yet, there is still scarce information on the comparative ability of the diverse SARS-CoV-2 vaccines to induce local IgA responses at the virus entry site. Thus, the aim of this study was to assess the presence of anti-SARS-CoV-2 IgA in the saliva of 95 subjects vaccinated with a booster dose and different combinations of vaccines, including mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech), and Vaxzevria (AstraZeneca). The results showed the presence of a mucosal response in 93.7% of vaccinated subjects, with a mean IgA titer of 351.5 ± 31.77 U/mL, strongly correlating with the serum anti-SARS-CoV-2 IgG titer (

Indexed as

COVID-19COVID-19 Vaccines2019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineHumansImmunizationImmunoglobulin AmRNA VaccinesSARS-CoV-22019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin AmRNA VaccinesCOVID-19IgAoral mucosal immunitySARS-CoV-2vaccine

Identifiers

PMID38140560
PMCPMC10748229
OpenAlexW4389055947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.